Jun 26, 2023

J.P. Morgan

January 2019:

ARTHEx S.L. participation at the 37th Annual J.P. Morgan Healthcare Conference, celebrated from January 7 to 10 2019 in San Francisco, California.

‍

Continue reading

November 11, 2024

ARTHEx Biotech Announces Oral Presentation on ATX-01 at TIDES Europe Annual Meeting 2024

ARTHEx Biotech Announces Oral Presentation on ATX-01 at TIDES Europe Annual Meeting 2024

This is some text inside of a div block.

by

November 7, 2024

ARTHEx Biotech Announces FDA Rare Pediatric Designation (RPD) of ATX-01 for the Treatment of Myotonic Dystrophy Type 1 (DM1)

ARTHEx Biotech Announces FDA Rare Pediatric Designation (RPD) of ATX-01 for the Treatment of Myotonic Dystrophy Type 1 (DM1)

This is some text inside of a div block.

by

October 18, 2024

ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)

ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)

This is some text inside of a div block.

by